The tax rate for the quarter was approximately 30.3%. Net earnings were
$44.8 million, or $0.69 per fully diluted share. Excluding the in-process
R&D write off and supply chain restructuring, adjusted net earnings were
$69.6 million and adjusted earnings per fully diluted share were $1.08.
Fourth Quarter Business Developments
-- Declared, in October, a $0.16 per share quarterly cash dividend, the
last quarterly dividend for 2007 which represents the 16th
consecutive increase in annual dividend payout.
-- Re-purchased approximately 537,000 shares of Beckman Coulter stock
at an average price of $69.71 per share, completing the company's
2.5 million share repurchase authorization.
-- Signed agreements with Johns Hopkins University, a leader in cancer
genomics research, that provide Beckman Coulter exclusive options to
license cancer genomics intellectual property that may arise from
its studies of multiple types of cancer including breast, colon and
six other cancers.
-- Acquired the remaining 80.1% of NexGen Diagnostics LLC, affording
access to technologies with the potential to greatly simplify future
immunoassay and molecular diagnostics testing.
-- Acquired the flow cytometry business of Dako Denmark AS,
significantly broadening Beckman Coulter's flow cytometry product
-- Renewed agreements valued at approximately $94 million per year with
MedAssets Supply Chain Systems, one of the nation's largest
healthcare group purchasing organizations, serving more than 125
health systems, includi
|SOURCE Beckman Coulter, Inc.|
Copyright©2008 PR Newswire.
All rights reserved